Naohito Inagaki

Down‐regulation of mitochondrial gene expression by the anti‐tumor arotinoid mofarotene (Ro 40‐8757)

Takafumi Uchida, Naohito Inagaki, Yasuhiro Furuichi et al. · International Journal of Cancer · 1994 · 17 citations

Medicine, Cancer Biology, Oncology +15

Development and Characterization of 1C6–203, a New Monoclonal Antibody Specific to Human Thymidine Phosphorylase

Toru Kono, Miwa Nishida, Naohito Inagaki et al. · Journal of Histochemistry & Cytochemistry · 2001 · 16 citations

Medicine, Oncology, Pharmacology +17

Erlotinib for Japanese Patients with Activating <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Combined Analyses from Two Phase II Studies

Shinji Atagi, Kōichi Goto, Takashi Seto et al. · Future Oncology · 2016 · 15 citations · Full text

Medicine, Oncology, Pharmacology +13

Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve <i>ALK</i> fusion positive non-small cell lung cancer (<i>ALK+</i> NSCLC).

Yuichi Takiguchi, Toyoaki Hida, Hiroshi Nokihara et al. · Journal of Clinical Oncology · 2017 · 15 citations

Medicine, Oncology, Pharmacology +14

Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients

Kiyotaka Yamazaki, Naohito Inagaki, Daniel Moldaver et al. · Cancer Science · 2020 · 13 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17